Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.

Wong AL, Lim JS, Sinha A, Gopinathan A, Lim R, Tan CS, Soh T, Venkatesh S, Titin C, Sapari NS, Lee SC, Yong WP, Tan DS, Pang B, Wang TT, Zee YK, Soong R, Trnkova Z, Lathia C, Thiery JP, Wilhelm S, Jeffers M, Goh BC.

J Transl Med. 2015 Feb 12;13:57. doi: 10.1186/s12967-015-0405-4.

2.

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group.

Clin Cancer Res. 2012 Apr 15;18(8):2290-300. doi: 10.1158/1078-0432.CCR-11-2175. Epub 2012 Feb 28.

3.

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T.

Eur J Cancer. 2012 Mar;48(4):465-74. doi: 10.1016/j.ejca.2011.12.026. Epub 2012 Jan 27.

PMID:
22285181
4.

Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.

Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S.

Gastrointest Cancer Res. 2011 Mar;4(2):40-4.

5.

Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.

Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. doi: 10.1007/s00280-011-1585-0. Epub 2011 Feb 25.

PMID:
21350850
6.

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, Hendlisz A.

J Clin Pharmacol. 2011 Dec;51(12):1674-84. doi: 10.1177/0091270010386226. Epub 2011 Jan 5.

PMID:
21209247
7.

Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.

Blumenschein GR Jr, Reck M, Fossella F, Stewart DJ, Lathia C, Peña C.

Cancer Biomark. 2011-2012;10(6):287-98. doi: 10.3233/CBM-2012-0253.

PMID:
22820084
8.

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.

Brendel E, Ludwig M, Lathia C, Robert C, Ropert S, Soria JC, Armand JP.

Cancer Chemother Pharmacol. 2011 Jul;68(1):53-61. doi: 10.1007/s00280-010-1423-9. Epub 2010 Sep 7.

9.

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.

Peña C, Lathia C, Shan M, Escudier B, Bukowski RM.

Clin Cancer Res. 2010 Oct 1;16(19):4853-63. doi: 10.1158/1078-0432.CCR-09-3343. Epub 2010 Jul 22.

10.

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.

Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L.

Anticancer Drugs. 2009 Aug;20(7):616-24.

PMID:
19739318
11.

The value, qualification, and regulatory use of surrogate end points in drug development.

Lathia CD, Amakye D, Dai W, Girman C, Madani S, Mayne J, MacCarthy P, Pertel P, Seman L, Stoch A, Tarantino P, Webster C, Williams S, Wagner JA.

Clin Pharmacol Ther. 2009 Jul;86(1):32-43. doi: 10.1038/clpt.2009.69. Epub 2009 May 27. Review.

PMID:
19474783
12.

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM.

J Clin Oncol. 2009 Jul 10;27(20):3312-8. doi: 10.1200/JCO.2008.19.5511. Epub 2009 May 18.

PMID:
19451442
13.

Recovery of microarray-quality RNA from frozen EDTA blood samples.

Beekman JM, Reischl J, Henderson D, Bauer D, Ternes R, Peña C, Lathia C, Heubach JF.

J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):44-9. doi: 10.1016/j.vascn.2008.10.003. Epub 2008 Nov 5.

PMID:
19028589
14.

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ.

Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123.

15.

A prototypical process for creating evidentiary standards for biomarkers and diagnostics.

Altar CA, Amakye D, Bounos D, Bloom J, Clack G, Dean R, Devanarayan V, Fu D, Furlong S, Hinman L, Girman C, Lathia C, Lesko L, Madani S, Mayne J, Meyer J, Raunig D, Sager P, Williams SA, Wong P, Zerba K.

Clin Pharmacol Ther. 2008 Feb;83(2):368-71. Epub 2007 Dec 19.

PMID:
18091762
16.

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.

Duran I, Hotté SJ, Hirte H, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL.

Clin Cancer Res. 2007 Aug 15;13(16):4849-57.

17.

Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.

Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW 2nd, Clark JI, Baar J, Sosman J, Weber J, Lathia C, Brunetti J, Cihon F, Schwartz B.

Clin Cancer Res. 2007 Jun 1;13(11):3312-9.

18.

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.

Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R.

Clin Cancer Res. 2007 May 1;13(9):2684-91.

19.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.

J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.

PMID:
16908937
20.

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ.

Clin Cancer Res. 2006 Jan 1;12(1):144-51.

21.

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.

Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR.

Anticancer Drugs. 2005 Oct;16(9):997-1002.

PMID:
16162976
22.

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies.

Chen EX, Batist G, Siu LL, Bangash N, Maclean M, McIntosh L, Miller WH Jr, Oza AM, Lathia C, Petrenciuc O, Seymour L.

Invest New Drugs. 2005 Oct;23(5):455-65.

PMID:
16133797
23.

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Stafford S, Waterfield B, Matthews S, Lathia C, Schwartz B, Agarwal V, Humphrey R, Seymour AL.

Invest New Drugs. 2005 Oct;23(5):437-43.

PMID:
16133795
24.

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.

Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P.

Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25.

PMID:
16133532
26.

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B.

Ann Oncol. 2005 Oct;16(10):1688-94. Epub 2005 Jul 8.

PMID:
16006586
27.

A phase I and pharmacokinetic study of BAY59: a novel taxane.

Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ.

Oncology. 2004;67(2):123-9.

PMID:
15539916
28.

An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.

Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L.

Invest New Drugs. 2005 Jan;23(1):63-71.

PMID:
15528982
29.

Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).

Ballow M, Berger M, Bonilla FA, Buckley RH, Cunningham-Rundles CH, Fireman P, Kaliner M, Ochs HD, Skoda-Smith S, Sweetser MT, Taki H, Lathia C.

Vox Sang. 2003 Apr;84(3):202-10.

PMID:
12670369
30.
31.

Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.

Lathia C, Fleming GF, Meyer M, Ratain MJ, Whitfield L.

Cancer Chemother Pharmacol. 2002 Aug;50(2):121-6. Epub 2002 Jun 28.

PMID:
12172976
32.

Effect of age and gender on the safety, tolerability, and pharmacokinetics of BAY 12-9566 in healthy subjects.

Lathia C, Shah A, Sundaresan P.

J Clin Pharmacol. 2001 Jul;41(7):764-9.

PMID:
11452709
33.

Distribution of [14C]suramin in tissues of male rats following a single intravenous dose.

McNally WP, DeHart PD, Lathia C, Whitfield LR.

Life Sci. 2000 Sep 1;67(15):1847-57.

PMID:
11043607
34.

Development of a chiral HPLC method to evaluate in vivo enantiomeric inversion of an unstable, polar radiosensitizer in plasma.

Kagel JR, Rossi DT, Hoffman KL, Leja B, Lathia CD.

J Pharm Biomed Anal. 1999 Nov;21(3):527-34.

PMID:
10701419
35.

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.

Bocan TM, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, Major T, Lathia C, Lee H.

Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):70-9.

PMID:
10634802
36.

Validated HPLC/MS/MS assay for CI-1011 in rat plasma and a comparison with an HPLC/UV assay.

Bullen WW, Lathia CD, Abel RB, Hayes RN.

J Pharm Biomed Anal. 1998 Sep;17(8):1399-413.

PMID:
9800659
37.

An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma.

Bullen WW, Rossi DT, Hoffman KL, Suri A, Lathia CD.

J Pharm Biomed Anal. 1997 Sep;16(1):47-55.

PMID:
9447551
38.
39.

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.

Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, Einzig AI, Wiernik PH.

Invest New Drugs. 1997;15(3):235-46.

PMID:
9387046
40.

Pharmacokinetic evaluation of zeniplatin in humans.

DeMarco LC, Budman DR, Lathia C, Amorusi P, Birkhofer M, Lichtman S, Weiselberg L, Vinciguerra V, Lovecchio J, Gal D, et al.

Cancer Chemother Pharmacol. 1995;36(1):35-40.

PMID:
7720173

Supplemental Content

Loading ...
Support Center